The tweet was deleted by the author.
But we saved everything 🙂.
Merck announced that the FDA has granted Priority Review for a new treatment option for certain patients with extensive-stage small cell lung cancer.
Merck is collaborating with Daiichi Sankyo on this development. The company shared a link for further information.
MRK is trading above the MA-20 ($118.35), MA-50 ($118.60), and well above the MA-200 ($97.43), confirming a strong upward structure for both the short, medium, and long term. The Ichimoku Kijun at $118.37 sits below the current price, acting as immediate support. Near-term support is at the cluster of MA-20 and Ichimoku Kijun around $118.35–$118.37, while the key support lies at the MA-50 ($118.60). Resistance is found near MA-5 ($121.48) and MA-10 ($120.71), with the key resistance at $122.49 marked by the HMA.
Momentum signals are moderately bullish on D1, with MACD indicating a buy and ADX remaining neutral. RSI and CCI are in buy territory, while Stoch RSI flashes a strong sell, resulting in some divergence among oscillators. BBP is overbought at 2.74, highlighting buyer dominance in the broader trend, yet intraday signals and some oscillators warn of possible short-term corrective pressure. AO supports the bullish trend, aligning with higher timeframe buys. MRK is trading at $121.41, up from a previous week close of $120.78—a 0.52% gain. The stock is positioned in the upper part of its weekly range, with weekly volatility at 6.44%. Price action this week shows consolidation near the highs after recovering sharply from the weekly low of $116.50. In today’s session, the stock slipped 1.04%, suggesting minor pullback after testing resistance.
Looking to the coming week, the expected price range for MRK is $119.22 to $124.00, keeping the stock well above its 52-week low of $73.31 and approaching the 52-week high of $125.14. The probability of further price increase is very high (more than 80%) based on bullish signals from RSI-W1, ADX-W1, MACD-W1, and MA-50-W1. The likelihood of a move lower is accordingly very low. Baseline scenario is sideways consolidation between $119.22 and $124.00. In a bullish scenario, a break above $124.00 opens the path toward a retest of the yearly high. On the downside, a dip below $119.22 would target the next cluster of support in the $118.35–$118.60 area, but the prevailing trend suggests downside risk is limited for now.
Previously, analysts noted that Merck was facing ongoing bearish momentum despite short-term gains, with caution advised amid weak underlying indicators. In light of the latest developments, traders should closely monitor for a sustained shift in trend direction, as confirmation of either renewed downside risk or a potential reversal remains key for the sessions ahead.